Oppenheimer Asset Management Inc. Has $2.47 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Oppenheimer Asset Management Inc. raised its stake in shares of Repligen Co. (NASDAQ:RGEN) by 16.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,574 shares of the biotechnology company’s stock after purchasing an additional 2,783 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Repligen were worth $2,467,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of RGEN. Evoke Wealth LLC bought a new position in Repligen during the fourth quarter worth $1,955,000. Norden Group LLC increased its position in Repligen by 1,711.6% during the first quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock worth $7,137,000 after acquiring an additional 36,663 shares during the period. Artemis Investment Management LLP increased its position in Repligen by 33.8% during the first quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after acquiring an additional 42,380 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Repligen by 30.2% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after acquiring an additional 6,705 shares during the period. Finally, Congress Asset Management Co. MA increased its position in Repligen by 14.6% during the first quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock worth $16,187,000 after acquiring an additional 11,213 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Stock Down 2.6 %

Shares of NASDAQ:RGEN opened at $136.39 on Wednesday. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The company’s fifty day moving average is $146.15 and its 200-day moving average is $156.04. The company has a market capitalization of $7.62 billion, a PE ratio of 545.56, a P/E/G ratio of 4.20 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. During the same quarter in the previous year, the company earned $0.53 EPS. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. Equities research analysts predict that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

RGEN has been the topic of a number of research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $190.00 target price on shares of Repligen in a research report on Wednesday, July 31st. Guggenheim started coverage on shares of Repligen in a research note on Tuesday, June 18th. They set a “neutral” rating on the stock. UBS Group decreased their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Stephens reiterated an “overweight” rating and set a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $188.38.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.